Seeking Alpha

Merck's (MRK +0.4%) MK-8931 Alzheimer's drug has entered Phase II trials, the company announces....

Merck's (MRK +0.4%) MK-8931 Alzheimer's drug has entered Phase II trials, the company announces. The drug attempts to prevent a worsening of Alzheimer's by blocking production of a protein believed to contribute to the disease. Eli Lilly (LLY) has reported positive Phase III trial results for its solanezumab Alzheimer's drug, when administered to patients with mild symptoms.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs